Polymorphisms in Genes Involved in Folate Metabolism as Risk Factors for NTDs

Summary

Moderate hyperhomocysteinemia in pregnant women has been associated with an increased risk of neural tube defects (NTDs). Periconceptional supplementation with multi-vitamins containing folic acid may normalize homocysteine metabolism and decrease the NTD risk. The C677 T variant of the MTHFR gene coding for a thermolabile enzyme has been described as the first genetic risk factor that accounts for a group of NTDs characterized by low maternal folate status and high homocysteine concentrations. Another common mutation of the same MTHFR gene, A1298 C, has also been described as an NTD risk factor. In addition to abnormal folate metabolism, anything that compromises the internalization of folate into the cell may be involved in the pathogenesis of NTDs. For this reason, a common polymorphism in the RFC-1 gene encoding the reduced folate carrier protein (A80 G) could also be an additional NTD risk factor. In the present study we examined the genotypic distributions and the allele frequencies of MTHFR A1298 C and RFC-1 A80 G polymorphisms in DNA samples from healthy Italian individuals and compared them to the frequencies observed in NTD cases and their parents. By means of restriction enzymatic analysis, we determined that the frequency of the mutated C allele of the A1298 C mutation was 0.25 among control individuals, which is in the range of that recently reported in other ethnic groups. However, we report that the mutant C allele frequencies are significantly higher among NTD cases and case mothers than among controls (0.39, 0.44, 0.25). Furthermore, for the RFC-1 A80 G mutation, we found that the frequency of the G allele of the RFC-1 mutation was 0.46 in the control population, suggesting that this is a common polymorphism in the Italian population. In spite of the high prevalence of the 80 G/G genotype among healthy subjects, we observed an increased frequency of the G allele in NTD-affected children, and their mothers and fathers. These preliminary results indicate that both the MTHFR and RFC-1 polymorphisms may play a role in NTD risk, at least in the Italian population. Further studies should be directed toward the evaluation of the level of risk conferred by the mutant MTHFR and RFC-1 genotypes, as well as the interaction between these genetic determinants and other nutritional and environmental factors.

Key words

NTDs - Folate metabolism and transport - MTHFR gene - RFC-1 gene - SNPs

References

• 1 Blom H J. Mutated 5, 10-methylenetetrahydrofolate reductase and moderate hyperhomocysteinaemia.  Eur J Pediatr. 1998;  157 S131-134
• 2 Botto L D, Yang Q. 5 - 10-methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE review.  Am J Epidemiol. 2000;  151 862-877
• 3 Brigle K E, Spinella M J, Sierra E E, Goldman I D. Characterization of a mutation in the reduced folate carrier in a transport defective L1210 murine leukemia cell line.  J Biol Chem. 1995;  270 22974-22979
• 4 Chango A, Emery-Fillon N, de Copurcy G P, Lambert D, Pfister M, Rosenblatt D S, Nicolas J P. A polymorphism (80 G → A) in the reduced folate carrier gene and its association with folate status and homocysteinemia.  Mol Genet Metab. 2000;  70 310-315
• 5 Chiao J H, Roy K, Tolner B, Yang C H, Sirotnak F M. RFC-1 gene expression regulates folate absorption in mouse small intestine.  J Biol Chem. 1997;  272 11165-11170
• 6 de Franchis R, Buoninconti A, Mandato C, Pepe A, Sperandeo M P, Del Gado R. et al . The C677 T mutation of the 5, 10-methylenetetrahydrofolate reductase gene is a moderate risk factor for spina bifida in Italy.  J Med Genet. 1998;  35 1009-1013
• 7 Friedman G, Goldschmidt N, Friedlander Y, Ben-Yehuda A, Selhub J, Babaey S. et al . A common mutation A1298 C in human methylenetetrahydrofolate reductase gene: association with plasma total homocysteine and folate concentrations.  J Nutr. 1999;  129 1656-1661
• 8 Frosst P, Blom H J, Milos R, Goyette P, Sheppard C A, Matthews R G, Boers G JH, den Heijer M, Kluijtmans L AJ, van den Heuvel L P, Rozen R. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase.  Nat Genet. 1995;  10 111-113
• 9 Kirke P N, Mills J L, Whitehead A S, Molloy A, Scott J M. Methylenetetrahydrofolate reductase mutation and neural tube defects.  Lancet. 1996;  348 1037-1038
• 10 Koch M C, Stegmann K, Ziegler A, Schroter B, Ermert A. Evaluation of the MTHFR C677 T allele and the MTHFR gene locus in a German spina population.  Eur J Pediatr. 1998;  157 487-492
• 11 Mills J L, McPartlin J M, Kirke P N, Lee Y J, Conley M R, Weir D G, Scott J M. Homocysteine metabolism in pregnancies complicated by neural-tube defects.  Lancet. 1995;  345 149-151
• 12 Mornet E, Muller F, Lenvoisè-Furet A, Delezoide A-L, Col J-Y, Simon-Bouy B, Serre J-L. Screening of the C677 T mutation on the methylenetetrahydrofolate reductase gene in French patients with neural tube defects.  Hum Genet. 1997;  100 512-514
• 13 Moscow J A, Gong M, He R, Sgagias M K, Dixon K H, Anzick S L, Melzer P S, Cowan K H. Isolation of a gene encoding a human reduced folate carrier (RFC1) and analysis of its expression in transport-deficient, methotrexate-resistant human breast cancer cells.  Cancer Res. 1995;  55 3790-3794
• 14 Vitamin Study Research Group M RC. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study.  Lancet. 1991;  338 131-137
• 15 Papapetrou C, Lynch S A, Burn J, Edwards Y H. Methylenetetrahydrofolate reductase and neural tube defects.  Lancet. 1996;  348 58
• 16 Rady P L, Tyring S K, Hudnall S D, Vargas T, Kellner L H, Nitowsky H, Matalon R K. Methylenetetrahydrofolate reductase (MTHFR): the incidence of mutations C677 T and A1298 C in the Ashkenazi Jewish population.  Am J Med Genet. 1999;  86 380-384
• 17 Speer M C, Worley G, Mackey J F, Melvin E, Oakes W J, George T M, Group N C. The thermolabile variant of methylenetetrahydrofolate reductase (MTHFR) is not a major risk factor for neural tube defect in American Caucasians.  Neurogenetics. 1997;  1 149-150
• 18 Scott J M, Weir D G, Molloy A, Mac Partlin J, Daly L, Kirke P. Folic acid metabolism and mechanisms of neural tube defects.  CIBA Foundation Symposium. 1994;  181 180-191
• 19 Shaw G M, Rozen R, Finnell R H, Todoroff K, Lammer E J. Infant C677 T mutation in MTHFR, maternal periconceptional vitamin use, and cleft lip.  Am J Med Genet. 1998;  80 196-198
• 20 Shaw G M, Rozen R, Finnell R H, Wasserman C R, Lammer E J. Maternal vitamin use, genetic variation of infant methylenetetrahydrofolate reductase, and risk for spina bifida.  Am J Epidemiol. 1998;  148 30-37
• 21 Shaw G M, Todoroff K, Finnell R H, Rozen R, Lammer E J. Maternal vitamin use, infant C677 T mutation in MTHFR, and isolated cleft palate risk.  Am J Med Genet. 1999;  85 84-85
• 22 Trembath D, Sherbondy A L, Vandyke D C, Shaw G M, Lammer E J, Finnell R H, Marker S, Lerner G, Murray J C. Analysis of select folate pathway genes, PAX3, and human T in a Midwestern neural tube defect population.  Teratology. 1999;  59 331-341
• 23 van der Put N MJ, Gabreëls F, Stevens E MB, Smeitink J AM, Trijbels F JM, Eskes T KAB, van den Heuvel L P, Mariman E CM, den Heyer M, Rozen R, Blom H J. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defect?.  Am J Hum Genet. 1995;  62 1044-1051
• 24 van der Put N MJ, van den Heuvel L P, Steegers-Theunissen R PM, Trijbels F JM, Eskes T KAB, Mariman E CM, Blom H J. Decreased methylenetetrahydrofolate reductase activity due to the C-T mutation in families with spina bifida offspring.  J Mol Med. 1996;  74 691-694
• 25 van der Put N MJ, Gabreëls F, Stevens E MB, Smeitink J AM, Trijbels F JM, Eskes T KAB, van den Heuvel L P, Blom H J. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factors for neural-tube defects?.  Am J Hum Genet. 1998;  62 1044-1051
• 26 Volcik K A, Blanton S H, Tyerman G H, Jong S T, Rott E J, Page T Z, Romaine N K. et al . Methylenetetrahydrofolate reductase and spina bifida: evaluation of level of defect and maternal genotypic risk in Hispanics.  Am J Med Genet. 2000;  95 21-27
• 27 Weisberg I, Tran P, Christensen B, Sibani S, Rozen R. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity.  Mol Genet Metab. 1998;  64 169-172
• 28 Whitehead A S, Gallagher P M, Mills Jl, Kirke P N, Burke H, Molloy A M, Weir D G. et al . A genetic defect in 5, 10 methylenetetrahydrofolate reductase in neural tube defects.  Q J Med. 1995;  88 763-766